These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1213 related articles for article (PubMed ID: 27250110)

  • 61. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
    Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
    J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines.
    Gao HL; Xia YZ; Zhang YL; Yang L; Kong LY
    Phytomedicine; 2019 May; 58():152885. PubMed ID: 31009836
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells.
    Rahman A; Husain SR; Siddiqui J; Verma M; Agresti M; Center M; Safa AR; Glazer RI
    J Natl Cancer Inst; 1992 Dec; 84(24):1909-15. PubMed ID: 1361008
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
    Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
    Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.
    Zheng Z; Aojula H; Clarke D
    J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
    Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
    Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
    Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Near-infrared triggered co-delivery of doxorubicin and quercetin by using gold nanocages with tetradecanol to maximize anti-tumor effects on MCF-7/ADR cells.
    Zhang Z; Xu S; Wang Y; Yu Y; Li F; Zhu H; Shen Y; Huang S; Guo S
    J Colloid Interface Sci; 2018 Jan; 509():47-57. PubMed ID: 28881205
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Reversal of multidrug resistance by guggulsterone in drug-resistant MCF-7 cell lines.
    Xu HB; Li L; Liu GQ
    Chemotherapy; 2011; 57(1):62-70. PubMed ID: 21282948
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer.
    Pan ZZ; Wang HY; Zhang M; Lin TT; Zhang WY; Zhao PF; Tang YS; Xiong Y; Zeng YE; Huang YZ
    Acta Pharmacol Sin; 2016 Aug; 37(8):1110-20. PubMed ID: 27292613
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin.
    Li H; Krstin S; Wink M
    Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo.
    Cao X; Luo J; Gong T; Zhang ZR; Sun X; Fu Y
    Mol Pharm; 2015 Jan; 12(1):274-86. PubMed ID: 25469833
    [TBL] [Abstract][Full Text] [Related]  

  • 73. An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance.
    Lu J; Zhao W; Liu H; Marquez R; Huang Y; Zhang Y; Li J; Xie W; Venkataramanan R; Xu L; Li S
    J Control Release; 2014 Dec; 196():272-86. PubMed ID: 25456831
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
    Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
    Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells.
    Gatouillat G; Magid AA; Bertin E; El btaouri H; Morjani H; Lavaud C; Madoulet C
    Phytomedicine; 2015 Dec; 22(13):1186-94. PubMed ID: 26598918
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Reversal of Multidrug Resistance by Apolipoprotein A1-Modified Doxorubicin Liposome for Breast Cancer Treatment.
    An D; Yu X; Jiang L; Wang R; He P; Chen N; Guo X; Li X; Feng M
    Molecules; 2021 Feb; 26(5):. PubMed ID: 33652957
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation.
    Xu H; Yang D; Cai C; Gou J; Zhang Y; Wang L; Zhong H; Tang X
    Acta Biomater; 2015 Apr; 16():156-68. PubMed ID: 25662165
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
    Mashayekhi S; Yousefi B; Tohidi E; Darband SG; Mirza-Aghazadeh-Attari M; Sadighparvar S; Kaviani M; Shafiei-Irannejad V; Kafil HS; Karimian A; Jadidi-Niaragh F; Majidinia M
    J Cell Biochem; 2019 Sep; 120(9):15719-15729. PubMed ID: 31087712
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
    Shen J; He Q; Gao Y; Shi J; Li Y
    Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
    Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
    Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.